Aprea Therapeutics (APRE) Projected to Announce Earnings on Tuesday

Aprea Therapeutics (NASDAQ:APRE) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Aprea Therapeutics to announce earnings of ($0.23) per share and revenue of $0.2530 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. On average, analysts expect Aprea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Price Performance

Shares of APRE traded up $0.00 during mid-day trading on Tuesday, hitting $0.60. 32,965 shares of the company’s stock were exchanged, compared to its average volume of 1,059,956. The company has a market cap of $7.44 million, a PE ratio of -0.39 and a beta of 1.52. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.83. The company has a 50-day simple moving average of $0.74 and a 200 day simple moving average of $0.78.

Wall Street Analyst Weigh In

APRE has been the topic of a number of research reports. Wedbush cut their price objective on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Finally, Oppenheimer initiated coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Aprea Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.07.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.